Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease
Thsi picture has been sued for representational purpose only
Pharma major Dr Reddy's Laboratories Ltd on Wednesday announced the launch of Avigan (Favipiravir) 200 mg tablets for treatment of Covid-19 in India.
ADVERTISEMENT
The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. Ltd that grants Dr Reddy's the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg tablets in India.
#Pharma major Dr. Reddy's Laboratories Ltd (@drreddys) on Wednesday announced the launch of Avigan (#Favipiravir) 200 mg tablets for the treatment of #Covid19 in India.
— IANS Tweets (@ians_india) August 19, 2020
Photo: IANS (Representational image) pic.twitter.com/MJJ7Ujz9ym
Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate Covid-19 disease.
"We are pleased to bring this important innovator medicine to the patients in India.AThe need for high quality and efficacy, affordability and better disease management are key priorities for us. We believe that Avigan would provide an effective treatment option to the Covid-19 impacted patients in India," said M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories.
Dr Reddy's Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.
To ensure accelerated access to the medicine, Dr Reddy's has initiated a free home delivery service in 42 cities in the country, and a helpline centre at 1800-267-0810/www.readytofightcovid.in between 9 a.m. to 9 p.m. Monday to Saturday.
Keep scrolling to read more news
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.
Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
